Qiagen stock heads into the open after a takeover-driven 4% jump
Published on 09/18/2026 at 07:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Qiagen stock closed at USD 44.28 on the New York Stock Exchange on September 17, 2026, marking a gain of 3.22% for the session per US quote data. The move left the shares clearly ahead of the broader US equity benchmarks on the same day, underlining how the takeover story dominated trading.
September 17, 2026 close in numbers
Qiagen N.V. (ISIN NL0012169213, NYSE: QGEN) saw its US listing finish at USD 44.28 on September 17, 2026, up from a prior close of USD 42.90, which corresponds to a 3.22% daily increase based on exchange data cited in market reports. An intraday snapshot around 10:34 US time showed the shares at USD 44.28, confirming that the closing level remained within the day’s trading range and above the prior session’s price. On the same day, the German DAX benchmark added 0.65% to close at 25,724.35 points, so Qiagen’s US move outpaced its home market’s headline index.
As Investing.com reported on September 17, 2026, the session was driven by a media report that several private equity firms are weighing offers for the molecular testing specialist, sending the shares up about 4% in morning trading. According to Barchart, names such as TPG and Bain Capital were cited among potential bidders, reinforcing existing takeover speculation. A separate note from GuruFocus highlighted that Qiagen’s shares traded near USD 43.73 against a GF Value measure of USD 49.41, providing valuation context that framed the takeover interest.
Takeover speculation shapes today’s outlook
Today, September 18, 2026, trading in Qiagen is set to open with investors still focused on the reported private equity interest and the possibility of formal bids in the coming days. As Boersen-Zeitung noted on September 17, 2026, a German magazine article discussing interest from several buyout firms, including TPG and Bain Capital, has rekindled takeover fantasies and pushed the stock toward recent highs in local trading. Without a scheduled earnings release or corporate event dated for today in the latest public calendars, the near-term path for Qiagen stock will likely hinge on any further news flow around strategic options, additional bidder names or management commentary on the review process ahead of the open.
